Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives

References

• Iismaa SE, Holman S, Wouters MA, Lorand L, Graham RM, Husain A. Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases. Proc Natl Acad Sci U S A. 2003;100(22):12636–12641. doi:10.1073/pnas.1635052100
   PubMed Web of Science ®Google Scholar
• Sarkar NK, Clarke DD, Waelsch H. An enzymically catalyzed incorporation of amines into proteins. Biochim Biophys Acta. 1957;25:451–452. doi:10.1016/0006-3002(57)90512-7
   PubMed Web of Science ®Google Scholar
• Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AVS. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med. 2000;6(3):337–342. doi:10.1038/73200
   PubMed Web of Science ®Google Scholar
• Martin A, de Vivo G, Gentile V. Possible role of the transglutaminases in the pathogenesis of Alzheimer’s disease and other neurodegenerative diseases. J Alzheimer’s Dis. 2011;2011:865432.
   Google Scholar
• Budillon A, Carbone C, Di Gennaro E. Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids. 2013;44(1):63–72. doi:10.1007/s00726-011-1167-9
   PubMed Web of Science ®Google Scholar
• Lee J, Condello S, Yakubov B, et al. Tissue transglutaminase mediated tumor–stroma interaction promotes pancreatic cancer progression. Clin Cancer Res. 2015;21(19):4482–4493. doi:10.1158/1078-0432.CCR-15-0226
   PubMed Web of Science ®Google Scholar
• Li B, Cerione RA, Antonyak M. Tissue transglutaminase and its role in human cancer progression. Adv Enzymol Relat Areas Mol Biol. 2011;78:247–293.
   PubMedGoogle Scholar
• Katt WP, Antonyak MA, Cerione RA. The diamond anniversary of tissue transglutaminase: a protein of many talents. Drug Discov. 2018;23(3):575–591.
   Google Scholar
• Katt WP, Antonyak MA, Cerione RA. Opening up about Tissue Transglutaminase: when Conformation Matters More than Enzymatic Activity. Med One. 2018;3(6):e180011. doi:10.20900/mo.20180011
   PubMedGoogle Scholar
• Keillor JW, Apperley KYP. Transglutaminase inhibitors: a patent review. Expert Opin Ther Pat. 2016;26(1):49–63. doi:10.1517/13543776.2016.1115836
   PubMed Web of Science ®Google Scholar
• Nurminskaya MV, Belkin AM. Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol. 2012;294:1–97. doi:10.1016/B978-0-12-394305-7.00001-X
   PubMed Web of Science ®Google Scholar
• Gundemir S, Colak G, Tucholski J, Johnson GV. Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta. 2011;1823(2):406–419. doi:10.1016/j.bbamcr.2011.09.012
   PubMed Web of Science ®Google Scholar
• Grenard P, Bates MK, Aeschlimann D. Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15: structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z*. J Biol Chem. 2001;276(35):33066–33078. doi:10.1074/jbc.M102553200
   PubMed Web of Science ®Google Scholar
• Liu S, Cerione RA, Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A. 2002;99(5):2743–2747. doi:10.1073/pnas.042454899
   PubMed Web of Science ®Google Scholar
• Pinkas DM, Strop P, Brunger AT, Khosla C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007;5(12):e327. doi:10.1371/journal.pbio.0050327
   PubMed Web of Science ®Google Scholar
• Achyuthan KE, Greenberg CS. Identification of a guanosine triphosphate-binding site on Guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem. 1987;262(4):1901–1906. doi:10.1016/S0021-9258(19)75724-X
   PubMed Web of Science ®Google Scholar
• Casadio R, Polverini E, Mariani P, et al. The structural basis for the regulation of tissue transglutaminase by calcium ions. Eur. J. Biochem. 1999;259:262. doi:10.1046/j.1432-1327.1999.00031.x
   PubMedGoogle Scholar
• Zhang JW, Lesort M, Guttmann RP, Johnson GVW. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J Biol Chem. 1998;273(4):2288–2295. doi:10.1074/jbc.273.4.2288
   PubMed Web of Science ®Google Scholar
• Eckert RL, Kaartinen MT, Nurminskaya M, et al. Transglutaminase regulation of cell function. Physiol Rev. 2014;94(2):383–417. doi:10.1152/physrev.00019.2013
   PubMed Web of Science ®Google Scholar
• Csősz É, Meskó B, Fésüs L. Transdab wiki: the interactive transglutaminase substrate database on web 2.0 surface. Amino Acids. 2009;36(4):615–617. doi:10.1007/s00726-008-0121-y
   PubMed Web of Science ®Google Scholar
• Kiraly R, Demeny M, Fesus L. Protein transamidation by transglutaminase 2 in cells: a disputed Ca2 + −dependent action of a multifunctional protein. FEBS J. 2011;1:278.
   Google Scholar
• Nakaoka H, Perez DM, Baek KJ, et al. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science. 1994;264(5165):1593–1596. doi:10.1126/science.7911253
   PubMed Web of Science ®Google Scholar
• Murthy SNP, Lomasney JW, Mak EC, Lorand L. Interactions of Gh/transglutaminase with phospholipase Cδ1 and with GTP. Proc Natl Acad Sci U S A. 1999;96(21):11815. doi:10.1073/pnas.96.21.11815
   PubMed Web of Science ®Google Scholar
• Mhaouty-Kodja S. Ghα/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell. 2004;96(5):363–367. doi:10.1111/j.1768-322X.2004.tb01427.x
   PubMed Web of Science ®Google Scholar
• Jang TH, Lee DS, Choi K, et al. Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site. PLoS One. 2014;9(9):e107005. doi:10.1371/journal.pone.0107005
   PubMed Web of Science ®Google Scholar
• Fields RD, Araque A, Johansen-Berg H, et al. Glial biology in learning and cognition. Neuroscientist. 2013;20(5):426–431. doi:10.1177/1073858413504465
   PubMed Web of Science ®Google Scholar
• von Bartheld CS. Myths and truths about the cellular composition of the human brain: a review of influential concepts. J Chem Neuroanat. 2018;93:2–15. doi:10.1016/j.jchemneu.2017.08.004
   PubMed Web of Science ®Google Scholar
• Freeman MR, Rowitch DH. Evolving concepts of gliogenesis: a look way back and ahead to the next 25 years. Neuron. 2013;80(3):613–623. doi:10.1016/j.neuron.2013.10.034
   PubMed Web of Science ®Google Scholar
• Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22(1):11–28. doi:10.1146/annurev.neuro.22.1.11
   PubMed Web of Science ®Google Scholar
• Hauwel M, Furon E, Canova C, Griffiths M, Neal J, Gasque P. Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, “protective” glial stem cells and stromal ependymal cells. Brain Res Rev. 2005;48(2):220–233. doi:10.1016/j.brainresrev.2004.12.012
   PubMedGoogle Scholar
• Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisén J. Identification of a neural stem cell in the adult mammalian central nervous system. Cell. 1999;96(1):25–34. doi:10.1016/S0092-8674(00)80956-3
   PubMed Web of Science ®Google Scholar
• Philips T, Rothstein JD. Oligodendroglia: metabolic supporters of neurons. J Clin Investig. 2017;127(9):3271–3280. doi:10.1172/JCI90610
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol. 2004;75(3):388–397. doi:10.1189/jlb.0303114
   PubMed Web of Science ®Google Scholar
• Rudlong J, Cheng A, Johnson GVW. The role of transglutaminase 2 in mediating glial cell function and pathophysiology in the central nervous system. Anal Biochem. 2020;591:113556. doi:10.1016/j.ab.2019.113556
   PubMed Web of Science ®Google Scholar
• Giera S, Luo R, Ying Y, et al. Microglial transglutaminase-2 drives myelination and myelin repair via GPR56/ADGRG1 in oligodendrocyte precursor cells. eLife. 2018;7:e33385. doi:10.7554/eLife.33385
   PubMed Web of Science ®Google Scholar
• Monteagudo A, Feola J, Natola H, Ji C, Pröschel C, Johnson GVW. Depletion of astrocytic transglutaminase 2 improves injury outcomes. Mol Cell Neurosci. 2018;92:128–136. doi:10.1016/j.mcn.2018.06.007
   PubMed Web of Science ®Google Scholar
• Elahi A, Emerson J, Rudlong J, et al. Deletion or inhibition of astrocytic transglutaminase 2 promotes functional recovery after spinal cord injury. bioRxiv. 2021;15:460455.
   Google Scholar
• Espitia Pinzon N, van Mierlo H, de Jonge JC, et al. Tissue transglutaminase promotes early differentiation of oligodendrocyte progenitor cells. Front Cell Neurosci. 2019;13:281. doi:10.3389/fncel.2019.00281
   PubMed Web of Science ®Google Scholar
• Monteagudo A, Ji C, Akbar A, Keillor JW, Johnson GVW. Inhibition or ablation of transglutaminase 2 impairs astrocyte migration. Biochem Biophys Res Commun. 2017;482(4):942–947. doi:10.1016/j.bbrc.2016.11.137
   PubMed Web of Science ®Google Scholar
• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–1850. doi:10.1001/jama.2013.280319
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology. 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299–312. doi:10.3322/caac.21613
   PubMed Web of Science ®Google Scholar
• Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol. 2021;151(1):41–53. doi:10.1007/s11060-020-03448-1
   PubMed Web of Science ®Google Scholar
• Zhang J, Antonyak MA, Singh G, Cerione RA. A mechanism for the upregulation of EGF receptor levels in glioblastomas. Cell Rep. 2013;3(6):2008–2020. doi:10.1016/j.celrep.2013.05.021
   PubMed Web of Science ®Google Scholar
• Boroughs LK, Antonyak MA, Cerione RA. A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival. J Biol Chem. 2014;289(14):10115–10125. doi:10.1074/jbc.M113.464693
   PubMed Web of Science ®Google Scholar
• Singh G, Zhang J, Ma Y, Cerione RA, Antonyak MA. The different conformational states of tissue transglutaminase have opposing effects on cell viability. J Biol Chem. 2016;291(17):9119–9132. doi:10.1074/jbc.M115.699108
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383. doi:10.1083/jcb.201211138
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Wilson KF, Cerione RA. R(h)oads to microvesicles. Small GTPases. 2013;3(4):219–224. doi:10.4161/sgtp.20755
   Google Scholar
• Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010;123(10):1603–1611. doi:10.1242/jcs.064386
   PubMed Web of Science ®Google Scholar
• Dyer LM, Schooler KP, Ai L, et al. The transglutaminase 2 gene is aberrantly hypermethylated in glioma. J Neurooncol. 2011;101(3):429–440. doi:10.1007/s11060-010-0277-7
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Singh US, Lee DA, et al. Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. J Biol Chem. 2001;276(36):33582–33587. doi:10.1074/jbc.M105318200
   PubMed Web of Science ®Google Scholar
• Yuan L, Choi K, Khosla C, et al. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther. 2005;4(9):1293–1302. doi:10.1158/1535-7163.MCT-04-0328
   PubMed Web of Science ®Google Scholar
• Gundemir S, Monteagudo A, Akbar A, Keillor JW, Johnson GVW. The complex role of transglutaminase 2 in glioblastoma proliferation. Neuro-Oncology. 2017;19(2):208–218. doi:10.1093/neuonc/now157
   PubMed Web of Science ®Google Scholar
• Sullivan KE, Rojas K, Cerione RA, Nakano I, Wilson KF. The cancer stem cell marker ALDH1A3 is the transcriptional regulator of the pharmaceutical target, tissue transglutaminase in mesenchymal glioma stem cells. Oncotarget. 2016;8:22325–22343. doi:10.18632/oncotarget.16479
   Google Scholar
• Daniel P, Meehan B, Rak J, et al. TGM2 novel biomarker of radiation response after neo-adjuvant TMZ in glioblastoma. Int J Radiat Oncol Biol Phys. 2020;108(3):e711–e712. doi:10.1016/j.ijrobp.2020.07.081
   Web of Science ®Google Scholar
• Berg TJ, Marques C, Pantazopoulou V, et al. The irradiated brain microenvironment supports glioma stemness and survival via astrocyte-derived transglutaminase 2. Cancer Res. 2021;81(8):2101. doi:10.1158/0008-5472.CAN-20-1785
   PubMed Web of Science ®Google Scholar
• Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M. Glioblastoma: microenvironment and niche concept. Cancers. 2019;11:1.
   Web of Science ®Google Scholar
• Yin J, Oh YT, Kim JY, et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling. Cancer Res. 2017;77(18):4973. doi:10.1158/0008-5472.CAN-17-0388
   PubMed Web of Science ®Google Scholar
• Pei J, Moon KS, Pan S, et al. Proteomic analysis between U87MG and U343MG-A cell lines: searching for candidate proteins for glioma invasion. Brain Tumor Res Treat. 2014;2(1):22–28. doi:10.14791/btrt.2014.2.1.22
   PubMedGoogle Scholar
• Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60(5):1383.
   PubMed Web of Science ®Google Scholar
• Oprita A, Baloi SC, Staicu GA, et al. Updated insights on EGFR signaling pathways in glioma. Int J Mol Sci. 2021;22:2. doi:10.3390/ijms22020587
   Web of Science ®Google Scholar
• Antonyak MA, Li B, Boroughs LK, et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A. 2011;108(12):4852–4857. doi:10.1073/pnas.1017667108
   PubMed Web of Science ®Google Scholar
• Keillor JW, Apperley KYP, Akbar A. Inhibitors of tissue transglutaminase. Trends Pharmacol Sci. 2015;36(1):32–40. doi:10.1016/j.tips.2014.10.014
   PubMed Web of Science ®Google Scholar
• Zhuang R, Khosla C. Substrates, inhibitors, and probes of mammalian transglutaminase 2. Anal Biochem. 2020;591:113560. doi:10.1016/j.ab.2019.113560
   PubMed Web of Science ®Google Scholar
• Dickson RB, Willingham MC, Pastan I. Binding and internalization of 125I-alpha 2-macroglobulin by cultured fibroblasts. J Biol Chem. 1981;256(7):3454–3459. doi:10.1016/S0021-9258(19)69630-4
   PubMed Web of Science ®Google Scholar
• Lorand L, Parameswaran KN, Stenberg P, et al. Specificity of Guinea-pig liver transglutaminase for amine substrates. Biochemistry. 1979;18(9):1756–1765. doi:10.1021/bi00576a019
   PubMed Web of Science ®Google Scholar
• Igarashi S, Koide R, Shimohata T, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet. 1998;18(2):111–117. doi:10.1038/ng0298-111
   PubMed Web of Science ®Google Scholar
• Basso M, Berlin J, Xia L, et al. Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation. J Neurosci. 2012;32(19):6561. doi:10.1523/JNEUROSCI.3353-11.2012
   PubMed Web of Science ®Google Scholar
• Jeitner TM, Pinto JT, Cooper AJL. Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo. Biosci. 2018;38:5.
   Web of Science ®Google Scholar
• Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol. 2005;12(4):469–475. doi:10.1016/j.chembiol.2005.02.007
   PubMed Web of Science ®Google Scholar
• Yuan L, Siegel M, Choi K, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene. 2007;26(18):2563–2573. doi:10.1038/sj.onc.1210048
   PubMed Web of Science ®Google Scholar
• Katt WP, Blobel NJ, Komarova S, Antonyak MA, Nakano I, Cerione RA. A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells. Oncotarget. 2018;9:34379–34397. doi:10.18632/oncotarget.26193
   PubMedGoogle Scholar
• Almami IS, Aldubayan MA, Felemban SG, et al. Neurite outgrowth inhibitory levels of organophosphates induce tissue transglutaminase activity in differentiating N2a cells: evidence for covalent adduct formation. Arch Toxicol. 2020;94(11):3861–3875. doi:10.1007/s00204-020-02852-w
   PubMed Web of Science ®Google Scholar
• Schuppan D, Mäki M, Lundin KEA, et al. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. N Engl J Med. 2021;385(1):35–45. doi:10.1056/NEJMoa2032441
   PubMed Web of Science ®Google Scholar
• Dafik L, Albertelli M, Stamnaes J, Sollid LM, Khosla C. Activation and Inhibition of Transglutaminase 2 in Mice. PLoS One. 2012;7(2):e30642. doi:10.1371/journal.pone.0030642
   PubMed Web of Science ®Google Scholar
• Pardin C, Roy I, Lubell WD, Keillor JW. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase. Chem Biol Drug Des. 2008;72(3):189–196. doi:10.1111/j.1747-0285.2008.00696.x
   PubMed Web of Science ®Google Scholar
• Apperley KY, Roy I, Saucier V, et al. Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition. MedChemComm. 2017;8(2):338–345. doi:10.1039/C6MD00565A
   PubMed Web of Science ®Google Scholar
• Case A, Stein RL. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry. 2007;46(4):1106–1115. doi:10.1021/bi061787u
   PubMed Web of Science ®Google Scholar
• Schneider MA, Heeb L, Beffinger MM, et al. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Sci Transl Med. 2021;13(611):eabc8188. doi:10.1126/scitranslmed.abc8188
   PubMed Web of Science ®Google Scholar
• Pinilla E, Comerma-Steffensen S, Prat-Duran J, et al. Transglutaminase 2 inhibitor LDN 27219 age-dependently lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries. Hypertension. 2021;77(1):216–227. doi:10.1161/HYPERTENSIONAHA.120.15352
   PubMed Web of Science ®Google Scholar
• Datta S, Antonyak MA, Cerione RA. GTP-binding-defective forms of tissue transglutaminase trigger cell death. Biochemistry. 2007;46(51):14819–14829. doi:10.1021/bi701422h
   PubMed Web of Science ®Google Scholar
• Colak G, Keillor JW, Johnson GVW. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PLoS One. 2011;6(1):e16665. doi:10.1371/journal.pone.0016665
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Pioglitazone hydrochloride in preventing head and neck cancer in patients with oral leukoplakia. ClinicalTrials.gov; 2003. Available from: https://clinicaltrials.gov/ct2/show/NCT00099021. Accessed October 3, 2021.
   Google Scholar
• National Cancer Institute. Rosiglitazone maleate in treating patients with oral leukoplakia. Clinicaltrials.gov; 2006. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00369174. Accessed October 3, 2021.
   Google Scholar
• Sulic AM, Kurppa K, Rauhavirta T, Kaukinen K, Lindfors K. Transglutaminase as a therapeutic target for celiac disease. Expert Opin Ther Targets. 2015;19:1–14. doi:10.1517/14728222.2014.985207
   PubMed Web of Science ®Google Scholar
• Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, Matei D. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer. Neoplasia. 2013;15(6):609–IN8. doi:10.1593/neo.121878
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Li B, Regan AD, Feng QY, Dusaban SS, Cerione RA. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem. 2009;284(27):17914–17925. doi:10.1074/jbc.M109.013037
   PubMed Web of Science ®Google Scholar
• Bordeleau F, Wang W, Simmons A, Antonyak MA, Cerione RA, Reinhart-King CA. Tissue transglutaminase 2 regulates tumor cell tensional homeostasis by increasing contractility. J Cell Sci. 2020;133(1):765.
   Web of Science ®Google Scholar
• Li B, Antonyak MA, Druso JE, Cheng L, Nikitin AY, Cerione RA. EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci U S A. 2010;107(4):1408–1413. doi:10.1073/pnas.0907907107
   PubMed Web of Science ®Google Scholar
• Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2006;103(24):9023–9028. doi:10.1073/pnas.0602681103
   PubMed Web of Science ®Google Scholar
• Shashidhar S, Lorente G, Nagavarapu U, et al. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene. 2005;24(10):1673–1682. doi:10.1038/sj.onc.1208395
   PubMed Web of Science ®Google Scholar
• Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48(3):417–433. doi:10.1016/j.immuni.2018.03.007
   PubMed Web of Science ®Google Scholar
• Huber V, Fais S, Iero M, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology. 2005;128(7):1796–1804. doi:10.1053/j.gastro.2005.03.045
   PubMed Web of Science ®Google Scholar
• Yin Y, Cai X, Chen X, et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014;24(10):1164–1180. doi:10.1038/cr.2014.121
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015;37(4):764–782. doi:10.1016/j.clinthera.2015.02.018
   PubMed Web of Science ®Google Scholar